Eric Vasiliauskas

Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

Paul Rutgeerts, Geert D’Haens, Stephan R. Targan et al. · Gastroenterology · 1999 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +10

Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease

Dermot McGovern, Michelle R. Jones, Kent D. Taylor et al. · Human Molecular Genetics · 2010 · 387 citations · Full text

Life Sciences, Genetics, Immunology +17

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Yukihide Momozawa, Julia Dmitrieva, Emilie Théâtre et al. · Nature Communications · 2018 · 252 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab

Konstantinos A. Papadakis, Omid Shaye, Eric Vasiliauskas et al. · The American Journal of Gastroenterology · 2005 · 165 citations

Medicine, Pharmacology, Pharmacotherapy +14

The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery

Cheryl Lau, Marla Dubinsky, Gil Melmed et al. · Annals of Surgery · 2014 · 156 citations

Medicine, Pharmacokinetics, Pharmacology +14